---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019856"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:46:38.821913+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics enters into $150M ATM equity offering agreement with BofA

## Summary
- Up to $150M in common stock may be sold at the company's discretion through BofA as sales agent or principal.
- BofA will receive up to 3% commission on gross proceeds; company also reimburses certain legal fees.
- Sales may occur via negotiated transactions, block trades, or at-the-market on Nasdaq.
- The offering is under an existing S-3 registration statement; no obligation to sell any shares.

## SEC filing metadata
- accession: 0000950170-23-019856
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017023019856/0000950170-23-019856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017023019856/janx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019856
- JSON: https://secwatch.observer/filing/0000950170-23-019856.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019856.txt

## Key facts
- Material Agreements
  Janux Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. valued at up to $150.0 million (effective 2023-05-09).
  - Action: entry
  - Agreement: atm program
  - Counterparty: BofA Securities, Inc.
  - Value: up to $150.0 million
  - Effective: 2023-05-09
  source text: On May 9, 2023, Janux Therapeutics, Inc. (the “Company”) entered into an ATM Equity OfferingSM Sales Agreement (the “Agreement”) with BofA Securities, Inc. (“BofA”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $150.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017023019856/0000950170-23-019856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.